Nuvation Bio (NUVB) is back in focus after reporting new patient-reported outcomes from its pivotal TRUST-II study of IBTROZI in advanced ROS1+ non small cell lung cancer, alongside fresh regulatory milestones.

The recent TRUST-II data and regulatory updates arrive after a mixed share price pattern, with a 30 day share price return of 7.03% and a year to date share price decline of 44.99%, while the 1 year total shareholder return is 92.65% and the 3 year total shareholder return is about 2.7x.

If progress in oncology trials has caught your attention, it may be worth widening your watchlist and checking out 39 healthcare AI stocks

With IBTROZI already approved in key markets and more regulatory decisions pending, the stock trades around US$4.72 with a value score of 3 and a sizeable gap to analyst targets. The key question for investors is whether there is genuine upside remaining or whether the market is already pricing in future growth.

Most Popular Narrative: 71.9% Undervalued

Against the last close of $4.72, the most followed narrative points to a fair value of about $16.80, rooted in a detailed view of Nuvation Bio's oncology pipeline and future cash flows.

Safusidenib targets a substantially larger glioma market than ROS1 lung cancer, with differentiated response data in both low and high grade IDH1 mutant disease and an FDA aligned pivotal Phase III design. This positions the asset as a potential second major commercial pillar that can accelerate long term revenue and earnings growth.

Curious what could justify a fair value several times above today's share price? The narrative leans on aggressive revenue expansion, rising margins and a punchy earnings multiple baked into a discounted cash flow view using a 6.96% rate. Want to see exactly how those pieces fit together and what assumptions have to hold for that outcome?

Result: Fair Value of $16.80 (UNDERVALUED)

However, this upbeat setup still hinges on IBTROZI holding share against other ROS1 therapies, and on safusidenib clearing a long, uncertain glioma trial timeline.

Another Angle On Valuation

The bullish fair value comes from a cash flow heavy narrative, but the market is still trading Nuvation Bio at a P/S of 11.5x versus 5.8x for the US Pharmaceuticals industry and 5.5x for peers, while the fair ratio sits higher at 14.5x. Is that a margin of safety or valuation risk for you?

Next Steps

Does the mix of optimism and caution here match your own read on Nuvation Bio, or does the data push you in a different direction? Take a closer look at the balance of upside and downside and then weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Nuvation Bio has sharpened your thinking, do not stop here, the wider market holds plenty of other stocks that could fit your style and goals.

• Target potential upside in undervalued opportunities by scanning the 47 high quality undervalued stocks.
• Prioritise resilience by checking companies in the 63 resilient stocks with low risk scores.
• Hunt for future standouts hiding in plain sight with the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.